TY  - JOUR
AU  - Perez-Belmonte, Luis M
AU  - Osuna-Sanchez, Julio
AU  - Millan-Gomez, Mercedes
AU  - Lopez-Carmona, Maria D
AU  - Gomez-Doblas, Juan J
AU  - Cobos-Palacios, Lidia
AU  - Sanz-Canovas, Jaime
AU  - Barbancho, Miguel A
AU  - Lara, Jose P
AU  - Jimenez-Navarro, Manuel
AU  - Bernal-Lopez, M Rosa
AU  - Gomez-Huelgas, Ricardo
PY  - 2019
DO  - 10.1080/07853890.2019.1613672
UR  - http://hdl.handle.net/10668/13895
T2  - Annals of medicine
AB  - Introduction: The use of dipeptidyl peptidase-4 inhibitors in hospitalized patients is an area of active research. We aimed to compare the efficacy and the safety of the basal-bolus insulin regimen versus linagliptin-basal insulin in non-critically...
LA  - en
PB  - Taylor & Francis
KW  - Diabetes mellitus
KW  - Inpatient hyperglycaemia
KW  - Linagliptin
KW  - Non-cardiac surgery
KW  - Aged
KW  - Blood Glucose
KW  - Diabetes Mellitus, Type 2
KW  - Dipeptidyl-Peptidase IV Inhibitors
KW  - Drug Therapy, Combination
KW  - Female
KW  - Glycated Hemoglobin
KW  - Hospitalization
KW  - Humans
KW  - Hypoglycemia
KW  - Hypoglycemic Agents
KW  - Insulin
KW  - Linagliptin
KW  - Male
KW  - Middle Aged
KW  - Safety
KW  - Spain
KW  - Treatment Failure
KW  - Treatment Outcome
TI  - Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.
TY  - research article
VL  - 51
ER  -